Davis's Drug Guide
ibritumomab
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
i-bri-too-mo-mab
To hear audio pronunciation of this topic, purchase a subscription or log in.Trade Name(s)
- Zevalin
Ther. Class.
Pharm. Class.
monoclonal antibodies
radioisotopes
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Ibritumomab." Davis's Drug Guide, 19th ed., F.A. Davis Company, 2024. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109636/all/ibritumomab.
Vallerand AHA, Sanoski CAC, Quiring CC. Ibritumomab. Davis's Drug Guide. F.A. Davis Company; 2024. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109636/all/ibritumomab. Accessed November 12, 2024.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2024). Ibritumomab. In Davis's Drug Guide (19th ed.). F.A. Davis Company. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109636/all/ibritumomab
Vallerand AHA, Sanoski CAC, Quiring CC. Ibritumomab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2024. [cited 2024 November 12]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109636/all/ibritumomab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - ibritumomab
ID - 109636
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109636/all/ibritumomab
PB - F.A. Davis Company
ET - 19
DB - Pediatrics Central
DP - Unbound Medicine
ER -
